[1]Iliescu L, Mindrut E, Grasu M, et al. Management of hepatocellular carcinoma - experience of a single center[J]. Chirurgia, 2014, 109(2):204-207. [2]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. [3]Zheng J, Kuk D, Gonen M, et al. Actual 10-year survivors after resection of hepatocellular carcinoma[J]. Ann Surg Oncol, 2017, 24(5):1358-1366. [4]Andreou A, Vauthey JN, Cherqui D, et al. Improved long-term survival after major resection for hepatocellular carcinoma:a multicenter analysis based on a new definition of major hepatectomy[J]. J Gastrointest Surg, 2013, 17(1):66-77. [5]Li M, Choo B, Wong ZM, et al. Expression of OCI-5/glypican 3 during intestinal morphogenesis:regulation by cell shape in intestinal epithelial cells[J]. Exp Cell Res, 1997, 235:3-12. [6]Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling[J]. Cancer Res, 2005, 65:6245-6254. [7]Cheng W, Tseng CJ, Lin TT, et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway[J]. Carcinogenesis, 2008, 29:1319-1326. [8]Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer[J]. Cell Cycle, 2008, 7:2787-2790. [9]Sung YK, Hwang SY, Farooq M, et al. Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling[J]. Exp Mol Med, 2003, 35:257-262. [10]Sakurai M, Shibata K, Umezu T, et al. Growth-suppressing function of glypican-3(GPC3)via insulin like growth factor II(IGF-II)signaling pathway in ovarian clear cell carcinoma cells[J]. Gynecol Oncol, 2010, 119:332-336. [11]Sandra IZ, Mariana IC, Wen S, Jorge F. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo[J]. Int J Cancer, 2010, 126:1291-1301. [12]Zhou F, Shang W, Yu X, Tian J. Glypican-3:A promising biomarker for hepatocellular carcinoma diagnosis and treatment[J]. Med Res Rev, 2017, 10. 1002/med. 21455. [13]Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(1):275-283. [14]Kwack MH, Choi BY, Sung YK. Cellular changes resulting from forced expression of Glypican-3 in hepatocellular Carcinoma cells[J]. Mol Cells, 2006, 21(2):224-228. [15] Lai JP, Sandhu DS, Yu CR, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases surv-ival in hepatocellular carcinoma[J]. Hepatology, 2008, 47(4):1211-1222. [16]Farooq M, Hwang SY, Park MK, et al. Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest[J]. Mol Cells, 2003, 15:356-360. [17]Capurro M, Martin T, Shi W, Filmus J. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling[J]. J Cell Sci, 2014, 127(7):1565-1575. [18]Sun CK, So SK. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2[J]. Neoplasia, 2011, 13(8):735-747. [19]Cartier F, Indersie E, Lesjean S, et al. New tumor suppressor microRNAs target glypican-3 in human liver cancer[J]. Oncotarget, 2017, 8(25):41211-41226. [20]Gao W, Kim H, Feng M, et al. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy[J]. Hepatology, 2014, 60(2):576-587. [21]Ikeda M, Ohkawa S, Okusaka T, et al. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma[J]. Cancer Sci, 2014, 105(4):455-462. [22]阮健. RNA干扰GPC3基因对肝癌huh-7细胞的生物学行为的影响[D]. 广州:南方医科大学, 2010. |